首页> 外文期刊>Experimental Animals >An animal model of attention deficit/hyperactivity disorder: A pharmacological perspective
【24h】

An animal model of attention deficit/hyperactivity disorder: A pharmacological perspective

机译:注意缺陷/多动障碍的动物模型:药理学角度

获取原文
获取原文并翻译 | 示例
           

摘要

Attention-deficit/hyperactivity disorder (AD/HD) is an early-onset neuropsychiatric disorder in children, symptomatically characterized by inattention and/or hyperactivity/impulsivity. Methylphenidate is commonly prescribed in the treatment of AD/HD. We have previously proposed male adolescent stroke-prone spontaneously hypertensive rats (SHRSP/Ezo) as an appropriate animal model of AD/HD, based on the symptomatic features. Male adolescent SHRSP/Ezo showed 1) attentional dysfunction (Y-maze test and 5-choice serial reaction time task), 2) hyperactivity (open-field test) and 3) impulsive behaviors based on low level of anxiety (elevated plus-maze test) as compared with genetic control Wistar-Kyoto rats. Interestingly, male but not female SHRSP/Ezo exhibited the attentional dysfunction, indicating the gender difference. SHRSP/Ezo also exerted the cortical hypoperfusion, as reported in AD/HD patients. Furthermore, angiogenic signaling molecules via VEGF/its receptors were down-regulated in the prefrontal cortex of SHRSP/Ezo. Those aberrant behaviors in SHRSP/Ezo, except for impulsivity, were ameliorated by clinical doses of methylphenidate. Attentional dysfunction in SHRSP/Ezo was also improved by atomoxetine and nicotinic agonists in the Y-maze test. Moreover, atypical antipsychotics (risperidone and olanzapine) and mood stabilizer (carbamazepine) ameliorated impulsive behaviors of SHRSP/Ezo in the elevated plus-maze test. Thus, the investigation in male adolescent SHRSP/Ezo might provide a breakthrough for exploring the pathogenesis and a novel insight for developing therapeutic agents for AD/HD.
机译:注意缺陷/多动障碍(AD / HD)是儿童的一种早发性神经精神障碍,其症状为注意力不集中和/或活动过度/冲动。在AD / HD的治疗中通常开处方哌醋甲酯。根据症状特征,我们先前曾提出雄性青少年中风倾向性自发性高血压大鼠(SHRSP / Ezo)作为AD / HD的适当动物模型。男性青少年SHRSP / Ezo表现为1)注意功能障碍(Y迷宫测试和5选择序列反应时间任务),2)多动症(开放视野测试)和3)基于低水平焦虑的冲动行为(正迷宫增强)测试)与遗传对照Wistar-Kyoto大鼠相比。有趣的是,男性而非女性SHRSP / Ezo表现出注意功能障碍,表明性别差异。正如AD / HD患者中报道的那样,SHRSP / Ezo还发挥了皮质灌注不足的作用。此外,在SHRSP / Ezo的前额叶皮层中,通过VEGF /受体的血管生成信号分子被下调。除冲动性外,SHRSP / Ezo中的异常行为可通过临床剂量的哌醋甲酯得到改善。在Y迷宫测试中,阿托西汀和烟碱激动剂也改善了SHRSP / Ezo的注意功能障碍。此外,非典型抗精神病药(利培酮和奥氮平)和情绪稳定剂(卡马西平)改善了高迷宫试验中SHRSP / Ezo的冲动行为。因此,对男性青少年SHRSP / Ezo的研究可能会为探索发病机理提供突破,并为开发AD / HD治疗剂提供新的见解。

著录项

  • 来源
    《Experimental Animals》 |2008年第3supa期|p.12|共1页
  • 作者

    Mitsuhiro Yoshioka;

  • 作者单位

    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 动物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号